AstraZeneca announces Q3 2026 financial results
Total revenue increased 7%, and the pipeline advanced with four new medicine approvals.
Latest AstraZeneca News & Updates
See the latest news and media coverage for AstraZeneca. We track all announcements, press releases, and industry mentions in real time, all in one place.
Science-led biopharmaceutical company
astrazeneca.com- Headquarters
- Cambridge, United Kingdom
- Company type
- Public company
- Number of employees
- 76,000+
- Industry
- Pharmaceuticals
Last updated
Latest news about AstraZeneca
In short: AstraZeneca won EU approval for Enhertu in early breast cancer and reported positive late-stage trial results.
Company announcements
AstraZeneca's Enhertu gets EU approval for early breast cancer
The European Commission approved the drug as adjuvant treatment. This follows positive data from the DESTINY-Breast05 trial demonstrating a 53% reduction in recurrence risk compared to standard care.
AstraZeneca reports positive SAFFRON trial results for Tagrisso plus Orpathys
The combination reduced progression or death risk by 45% and death risk by 32% in EGFR-mutated lung cancer patients progressing on prior therapy. AstraZeneca submitted an NDA to the FDA based on these findings.
AstraZeneca reports positive VOLGA trial results for Imfinzi and EV in bladder cancer
The regimen reduced recurrence risk by 49% and death risk by 42%, supporting FDA Priority Review.
Media coverage
COVID Vaccine Giant AstraZeneca Stock Jumps 7%. What's Behind It?
AstraZeneca Q3 earnings beat forecasts as the drugmaker launches a $1.5 billion savings plan to fund its AI-backed pipeline.
AstraZeneca cans late-stage Ultomiris trial on lacklustre efficacy predictions
Ultomiris, one of AstraZeneca’s blockbuster sellers in Q3, is currently approved across five rare di...
AstraZeneca Q3 Profit Rises; Pipeline Delivers 12 Positive Phase 3 Readouts; Stock Up
The Phase 3 CROSSING trial met its primary endpoints in eosinophilic esophagitis, showing improvements in histologic and endoscopic remission and dysphagia symptoms. Positive high-level results...
AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock
AstraZeneca aims to free up funds to reinvest into its pipeline and meet its goal of $80 billion in annual revenue by 2030.
Never miss news about AstraZeneca
Track AstraZeneca and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
AstraZeneca competitors & trending companies
Browse news for competitors to AstraZeneca and other trending companies.